Carmot Therapeutics is a clinical stage biotechnology company dedicated to the discovery and development of innovative medicines for the treatment of metabolic diseases, cancer, and inflammation. Carmot has developed a transformative drug discovery approach, Chemotype Evolution, that overcomes major limitations in existing drug discovery approaches and provides a unique opportunity to tackle challenging disease targets. We have a broad metabolic pipeline and a portfolio of wholly-owned programs targeting class-B GPCRs and deubiquitinating enzymes, including our lead compound, CT-868, which is progressing toward Phase 2 clinical trials. Carmot is seeking a dedicated and experienced in vivo pharmacologist with experience in metabolic disease models to help advance multiple discovery programs toward clinical development.
In this position you will be responsible for designing and executing in vivo studies to expand Carmot’s internal pipeline. You will be utilizing in vivo metabolic disease models for compound characterization and mechanism of action studies. These efforts will support lead discovery and translational biology for clinical compounds. You will have the opportunity to lead new initiatives and impact programs from early discovery to through IND enabling studies. Carmot is a dynamic and fast-paced environment with a strong culture of innovation, initiative and ownership. You must be excellent at balancing priorities and integrating into a multi-disciplinary team.
Required experience and skills: